Clinical TrialMay 5, 2026, 07:13 AM
Ocular Therapeutix AXPAXLI Phase 3 SOL-1 Positive; Q1 Net Loss $(88.6)M
AI Summary
Ocular Therapeutix reported its first quarter 2026 financial results and significant business highlights, primarily driven by positive Phase 3 SOL-1 results for AXPAXLI in wet AMD. The trial demonstrated superior visual outcomes and sustained disease control, leading to accelerated commercial preparedness and plans for an NDA submission. The company reported a Q1 2026 net loss of $(88.6) million, with a strong cash balance of $666.7 million providing a runway into 2028.
Key Highlights
- AXPAXLI Phase 3 SOL-1 met primary endpoint (p=0.0006) for vision maintenance at Week 36.
- 74.1% of AXPAXLI subjects maintained vision at Week 36 in SOL-1; 65.9% at Week 52.
- Enrollment began in SOL-X long-term extension trial for wet AMD in April 2026.
- Q1 2026 Net Loss: $(88.6) million, or $(0.40) per share.
- Q1 2026 Total Net Revenue: $10.8 million, a 0.8% increase YoY.
- Cash balance: $666.7 million as of March 31, 2026, with runway into 2028.
- Investor Day scheduled for June 17, 2026, for program and regulatory updates.